• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

    342.94 -1.81 (-0.53%)
    Streaming Delayed Price Updated: 2:36 PM EDT, Aug 31, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 166,541
    Open 343.00
    Bid (Size) 342.50 (480)
    Ask (Size) 344.68 (160)
    Prev. Close 344.75
    Today's Range 333.46 - 347.21
    52wk Range 37.19 - 392.70
    Shares Outstanding 44,712,538
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Praxis (PRAX) Q2 2026 Earnings Call Transcript ↗
    Two FDA applications advance as cash runway extends into 2028. 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Praxis Precision Medicines Q2 Earnings Call Highlights ↗
    Praxis Precision Medicines (NASDAQ:PRAX) said it is preparing for potential commercial launches of ulixacaltamide for essential tremor and relutrigine for SCN2A- and SCN8A-related developmental and... 
    Via MarketBeat
    Topics Earnings

    Performance

    YTD
    +19.7%
    +19.7%
    1 Month
    +11.4%
    +11.4%
    3 Month
    +2.3%
    +2.3%
    6 Month
    +3.7%
    +3.7%
    1 Year
    +663.1%
    +663.1%

    More News

    Read More
    News headline image
    Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    Praxis Precision Medicines Provides Vormatrigine Program Update
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    News headline image
    This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1 ↗
    Via The Motley Fool
    Topics Regulatory Compliance Stocks
    News headline image
    Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗
    Via The Motley Fool
    Topics Intellectual Property Regulatory Compliance
    News headline image
    Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year ↗
    Via The Motley Fool
    Topics Economy Regulatory Compliance
    News headline image
    Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗
    Via The Motley Fool
    News headline image
    Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally ↗
    Via The Motley Fool
    News headline image
    Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy ↗
    Via The Motley Fool
    Topics Regulatory Compliance

    Frequently Asked Questions

    Is Praxis Precision Medicines, Inc. - Common Stock publicly traded?
    Yes, Praxis Precision Medicines, Inc. - Common Stock is publicly traded.
    What exchange does Praxis Precision Medicines, Inc. - Common Stock trade on?
    Praxis Precision Medicines, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Praxis Precision Medicines, Inc. - Common Stock?
    The ticker symbol for Praxis Precision Medicines, Inc. - Common Stock is PRAX on the Nasdaq Stock Market
    What is the current price of Praxis Precision Medicines, Inc. - Common Stock?
    The current price of Praxis Precision Medicines, Inc. - Common Stock is 342.94
    When was Praxis Precision Medicines, Inc. - Common Stock last traded?
    The last trade of Praxis Precision Medicines, Inc. - Common Stock was at 08/31/26 02:36 PM ET
    What is the market capitalization of Praxis Precision Medicines, Inc. - Common Stock?
    The market capitalization of Praxis Precision Medicines, Inc. - Common Stock is 15.33B
    How many shares of Praxis Precision Medicines, Inc. - Common Stock are outstanding?
    Praxis Precision Medicines, Inc. - Common Stock has 15B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.